The World Health Organization (WHO) is launching a project that aims to accelerate development and accessibility of vaccines for highly pathogenic avian influenza (HPAI or H5N1) mRNA vaccines for manufacturers in low- and middle-income countries, it announced Monday (July 29). Argentinian manufacturer Sinergium Biotech will partner with WHO on the effort, leveraging technologies from the Medicines Patent Pool (MPP) mRNA Technology Transfer Program. Sinergium is aiming to establish proof-of-concept preclinical models for candidate H5N1 vaccines which, once established, would be...